DEA lets university import pot extracts

Dr. Fatta Nahab, a neurologist at the University of California San Diego, spent years working to get approval to import marijuana from Canada to study whether cannabis can be used to treat essential tremor, a shaking condition affecting millions of people.
Dr. Fatta Nahab, a neurologist at the University of California San Diego, spent years working to get approval to import marijuana from Canada to study whether cannabis can be used to treat essential tremor, a shaking condition affecting millions of people.

SAN DIEGO -- In a rare move, the U.S. government has approved the importation of marijuana extracts from Canada for a clinical trial, highlighting a new avenue for American researchers who have long had trouble obtaining the drug for medical studies.

The University of California San Diego's Center for Medicinal Cannabis Research announced Tuesday that the Drug Enforcement Administration has approved its plans to import capsules containing two key cannabis compounds -- CBD (cannabidiol) and THC (tetrahydrocannabinol, the principal psychoactive ingredient in marijuana) -- from British Columbia's Tilray Inc. to study their effectiveness in treating tremors that afflict millions of people, especially those over 65.

Marijuana remains illegal under federal law, making it impossible for researchers to simply obtain forms of the drug from one of the many medical-marijuana programs approved by individual states -- even a state with a pot culture as prevalent as California's.

Instead, federal law dictates that researchers typically must obtain any weed for clinical trials through the National Institute on Drug Abuse, which uses cannabis grown at the University of Mississippi. Scientists have long complained about the difficulty of obtaining that marijuana, as well as its limited quality, variety and usefulness for clinical research.

The University of California San Diego researchers said they needed marijuana extracts in capsule form because it's easier to monitor the doses that patients receive, compared to having patients smoke or vaporize it. They also believed many older patients would be reluctant to participate in the study if they had to inhale the drug, according to Dr. Fatta Nahab, a university neurologist and the tremor study's principal investigator.

The institute doesn't offer capsules, so the researchers spent about two years going through regulatory hoops to obtain permission to import the drug from Canada, where medical marijuana is federally legal and where recreational sales begin nationwide next month.

Paul Armentano, deputy director of a pro-pot advocacy group, the National Organization for the Reform of Marijuana Laws, said that illustrates how badly American researchers need alternative sources for cannabis. The House Judiciary Committee last week passed a bill to require the Justice Department to issue at least two more licenses to U.S. facilities to grow pot for research.

"It's very telling that you have researchers in the U.S. willing to exert the patience and go through the regulatory hurdles to make this happen at the same time the United States has its own domestic supply source," Armentano said.

Marijuana compounds have been imported for clinical trials before, including by Britain's GW Pharmaceuticals, which won approval this year to sell its purified CBD capsule, Epidiolex, to treat severe forms of epilepsy -- the first cannabis drug approved by the U.S. Food and Drug Administration. While GW Pharmaceuticals developed that drug in-house before sending it to the U.S. for testing, Tilray, which recently became the first marijuana company to complete an initial public stock offering in the U.S., said it can work with researchers to develop the cannabis formulations the company hopes to study.

"It's a really big milestone for Tilray and also just for the whole industry," said Catherine Jacobson, Tilray's director of clinical research. "Researchers in the U.S. have really been limited to doing research using dried flower. We have been able to prove to the FDA that we can manufacture investigational study drugs containing cannabinoids that meet their standards."

Neither the Food and Drug Administration, which regulates clinical trials, nor the DEA had immediate details on how often the agencies have approved the import or use of foreign-made cannabis drugs in research, but DEA spokesman Katherine Pfaff said: "It is done. There are definitely situations where, when there's no source in the U.S., a registrant can import a cannabis-derived drug from another country."

The National Institute on Drug Abuse usually provides marijuana as bulk flower or joints to be vaporized or smoked, though it also can supply cannabis oil.

The institute intends to expand how much marijuana the University of Mississippi grows for research. The agency's contract with the university provides for the possibility of offering cannabis capsules, but it has not yet done so, said Don Stanford, assistant director of the Research Institute of Pharmaceutical Sciences at the university.

There is no drug designed to treat essential tremor, a shaking condition. Unlike Parkinson's disease, which causes shaking when the person is not moving, people with essential tremors shake when they are, making everyday activities like writing, drinking and speaking difficult. The condition afflicts 10 million people nationally and millions more across the globe, according to the International Essential Tremor Foundation.

Many patients try to control the shaking by repurposing other drugs, such as blood pressure medicine, with limited success.

Tilray, which has seen its valuation double since the beginning of the month, could become a $100 billion company, according to its chief executive officer, as the regulations surrounding marijuana continue to ease across the globe.

Tilray is interested in the burgeoning market for consumer products that use ingredients from marijuana, CEO Brendan Kennedy said in an interview in New York on Tuesday. "We've had lots of conversations with lots of companies," he said, though he declined to provide specific details about any potential partnerships.

Information for this article was contributed by Gene Johnson and Julie Watson of The Associated Press; and by Craig Giammona and Janet Freund of Bloomberg News.

Business on 09/19/2018

Upcoming Events